has announced a collaboration with the Florey Institute of Neuroscience and Mental Health under which they will develop tissue therapies for the treatment of neurological diseases.
Tessara said the initial focus will be on the development of tissue therapy TTX‑001 for Parkinson’s disease (PD). Development work at the Florey Institute will take place in the laboratories of Professor David Finkelstein, the head of the Parkinson’s Disease Laboratory, and Professor Paul Adlard, the head of the Synaptic Neurobiology Laboratory.
TTX-001 is an off-the-shelf, dopamine-replacement and neuroprotective RealBrain micro-tissue therapy under development as a disease-modifying and regenerative treatment with improved clinical and quality-of-life outcomes for patients living with PD.